Outpatient Liquid Aspirin (OLA) (OLA COVID)

Outpatient, Liquid Aspirin to Reduce COVID-19 Hospitalizations

The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insufficiency or failure.

Study Overview

• Status: Recruiting
• Conditions: Covid19
• Intervention / Treatment: Drug: ASA

Detailed Description

200 people will take part in this LSUHSC-NO and its affiliates study.

The clinical site will offer study enrollment to newly diagnosed COVID-19 patients at the time of diagnosis. Contact information will be shared with study team in a HIPAA compliant manner on the same day. Within 24 hours, our Study staff will contact patient for recruitment and enrollment. Within 48 hours of enrollment, the patient will come to a study site for randomization to treatment arms, to be provided a no-cost supply of the treatment which they are assigned, and for blood draws that help determine their risk of developing severe COVID disease. Patients will be assigned to either:

Arm 1: Placebo

Or

Arm 2: Treatment with liquid aspirin 150 mg daily. (ASA 150).

Study staff will follow-up every 2 days for a total of 30 days by text/phone/telemedicine to monitor changes in their health status, hospitalization rates, and encourage adherence to the treatment arm. Between days 7 and 10 of the study, patients will undergo repeat blood draws to help ensure their safety with regards to COVID-19. If they become hospitalized due to COVID-19, their participation will extend until they are discharged from the hospital. Medical records will be reviewed to collect data including demographics, medical comorbidities, laboratory data and hospitalization course. After 30 days of treatment, weekly follow up for another 30 days will take place ensure no late, adverse events occurred.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • Recruiting
      • Lsuhsc-No
      • Contact: Catherine Powell, MS; Phone Number: 504-568-2202

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients > 40 years
• Written informed consent
• New (within 24 hours) COVID-19 diagnosis
• Serum 25OHD levels drawn at time of COVID-19 laboratory workup

Exclusion Criteria:

• Asymptomatic patients
• Patients already taking ASA and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban.
• Pregnant patients or prisoners
• History of GI bleeding or peptic ulcer disease, or spontaneous bleeding from other sites
• Thrombocytopenia (platelets <130,000/uL) at time of COVID diagnosis
• Anemia at time of COVID diagnosis (defined as hemoglobin level <12 g/dl in men or <11 g/dl in women)22
• History of chronic kidney disease
• Concurrent use of nonsteroidal anti-inflammatory drugs, or steroids
• Hypervitaminosis D and associated risk factors: Renal failure, Liver failure, Hyperparathyroidism, Sarcoidosis, Histoplasmosis
• Known allergy to Aspirin
• Inability to tolerate oral medications
• Known history of aspirin-induced asthma
• History of bleeding problems
• Patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of ASA treatment
• Patients who cannot stop taking other nonprescription NSAIDs (ibuprofen, naproxen, or others) during the 30-day course of ASA treatment
• Patients requiring hospitalization (for any reason) at time of screening
• Patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of COVID

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.	Drug: ASA; Liquid aspirin formulation
ACTIVE_COMPARATOR: Liquid ASA; Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days	Drug: ASA; Liquid aspirin formulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduced COVID-19 related hospitalizations	To obtain reliable and interpretable data to inform future trials regarding our hypothesis that a 30 day treatment course of COVID patients with a novel, liquid aspirin formulation can reduce hospitalizations driven by COVID associate coagulopathy (CAC)	6 months

Collaborators and Investigators

• Sponsor: Louisiana State University Health Sciences Center in New Orleans
• Collaborators: Innovate Anti-Infectives

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 6, 2021
• Primary Completion (ANTICIPATED): December 5, 2022
• Study Completion (ANTICIPATED): December 5, 2022

Study Registration Dates

• First Submitted: June 16, 2021
• First Submitted That Met QC Criteria: June 16, 2021
• First Posted (ACTUAL): June 23, 2021

Study Record Updates

• Last Update Posted (ACTUAL): January 3, 2022
• Last Update Submitted That Met QC Criteria: December 13, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 1658

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No